Patience John's Form 4 filing
Accelerate Diagnostics, Inc (AXDX) · filed Jan 25, 2024
- Accession no.
- 0001104659-24-006670
- Filed
- Jan 25, 2024
- Trade date
- Jan 23, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction and 1 derivative transaction. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Patience JohnCIK 0001021413 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 23, 2024 | Common Stock | PPurchaseAcquired | +16,666 | –F1 | – | 453,224 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 23, 2024 | Common Stock | PPurchaseAcquired | +16,666 | –F1 | – | 16,666 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The reported securities are included within 16,666 units of the issuer (the "Units") purchased by the reporting person for $1.50 per Unit in an underwritten public offering. Each Unit consists of one share of the issuer's common stock and one warrant to purchase one share of the issuer's common stock.
Referenced by the price of 1 transaction in Table I and 1 transaction in Table II.
Remarks
On July 11, 2023, the issuer effected a reverse stock split of its common stock at a ratio of 1-for-10 (the "Reverse Stock Split"). As a result of the Reverse Stock Split, proportionate adjustments were made to the number of shares of the issuer's common stock underlying its outstanding equity awards, warrants and convertible notes, as well as the exercise or conversion price, as applicable. The amounts reported herein (and to be reported in subsequent reports) have been adjusted to reflect the Reverse Stock Split.